Novo Nordisk remains one of the best-positioned companies in the treatment of diabetes and obesity, benefiting from strong brands (such as Ozempic and Wegovy), a consolidated global presence, and a promising pipeline.
Despite the sharp drop in its shares, the company maintains solid fundamentals, strong cash generation, and medium-term prospects for double-digit annual growth.
The main risks come from fierce competition with Eli Lilly, tariffs, pricing pressure, and excessive reliance on semaglutide.
However, ongoing innovation, investment in oral therapies, development of new areas of activity, and strategic partnerships strengthen Novo Nordisk’s competitive capacity in order to preserve its wide moat.
For long-term investors, the current correction may represent an attractive entry opportunity.
